Jan 10, 2020 13:18 JST

Source: SinoMab BioScience Limited

SinoMab Granted the "Most Popular Newly Listed Company" Award

HONG KONG, Jan 10, 2020 - (ACN Newswire) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the Group has won the title of the "Most Popular Newly Listed Company" at the 4th Hong Kong Golden Stocks Awards held in Shenzhen.

 


The 4th Hong Kong Golden Stocks Awards was jointly organized by Zhitongcaijing.com, China's leading information platform focusing on Hong Kong and US stock markets, and 10jka.com.cn. The "Most Popular Newly Listed Company" award aims at recognizing companies had been listed on Hong Kong Stock Exchange since 1 January 2019 with significant recognition from the industry, high participation of investors and excellent performance in capital markets. Being awarded the "Most Popular Newly Listed Company" demonstrates the industry and investors' close attention towards biotech industry and is a great encouragement and motivation for SinoMab's future success. SinoMab, as the first Hong Kong-listed local biopharmaceutical company, possesses several first-in-target and first-in-class drug candidates. As the drug candidate coming the closest to commercialization, the Company's flagship product SM03 is currently in Phase III clinical trial for RA in China and is expected to be marketed in 2021 the soonest. According to the latest statistics, approximately 300 patients have taken the treatment trial. Meanwhile, the Company has proactively carried out long-term development plan. Its Suzhou production base is expected to be put into operation by the end of 2021 to satisfy the commercialized production requirements of drug candidates in the future.

After three months of strict screening, the 4th Hong Kong Golden Stocks Awards attracted over 860 Hong Kong-listed companies to participate, covering emerging industries such as TMT and healthcare. The award is a recognition of SinoMab's R&D strengths, business model and industry influence from the market and investors and will help improving the Company's reputation in the capital market.

About SinoMab BioScience Limited
SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis, systemic lupus erythematosus, non-Hodgkin's lymphoma, asthma, and other diseases with major unmet clinical needs.



Source: SinoMab BioScience Limited
Sectors: Daily Finance, Daily News, BioTech

Copyright ©2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Related Press Release


SinoMab Awarded the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of the "6th Hong Kong Golden Stocks Awards" and the "Listed Company with the Most Growth Potential" in the Selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies"
January 11 2022 16:55 JST
 
SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03
November 30 2021 20:50 JST
 
SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health
November 26 2021 18:26 JST
 
SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases
September 17 2021 08:40 JST
 
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SN1011 in China
January 18 2021 08:30 JST
 
SinoMab Commenced Construction of its China Headquarters
November 23 2020 15:20 JST
 
SinoMab entered into Strategic Collaboration with D2M
July 23 2020 07:20 JST
 
SinoMab Announces Clinical Results on its First-in-target SM03 at EULAR 2020 Congress
June 10 2020 07:52 JST
 
Great Potential in RA Therapeutic Market, Sinomab Announces Latest Progress of its Drug Candidate SM03 Phase III Clinical Trial for the Treatment RA
November 20 2019 16:34 JST
 
SinoMab BioScience Announces Proposed Listing on the Main Board of SEHK
October 30 2019 18:50 JST
 
More Press release >>

Latest Press Release


More Latest Release >>